The effectiveness of magnesium sulfate nebulizer in treatment of acute bronchiolitis

Modaresi, Mohammadreza; Faghihinia, Jamal; Mirlohi, H.; Pjang, F.

doi:10.1016/s1526-0542(12)70078-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alansari et al evaluated the role of intravenous magnesium sulphate in a cohort of 162 children and concluded that it did not provide any benefit [7]. Amongst the studies on nebulized MgSO 4 , noteworthy is the research by Modaresi et al [9,13]. They conducted two studies with 60 and 120 children in 2012 and 2015, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nebulized Magnesium Sulphate in Bronchiolitis: A Randomized Controlled Trial

et al. 2021

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of nebulized magnesium sulphate as a bronchodilator in young children aged 1-24 mo with moderate to severe bronchiolitis in comparison to standard therapy. Methods This was an open labeled randomized controlled trial comprising 60 children with moderate to severe bronchiolitis which was randomly assigned to 2 groups. Intervention group received nebulization with 3 mL of 3.2% magnesium sulphate (MgSO 4 ) (iso-osmolar) every 4 hourly for 24 h in addition to standard care and the control group received standard care alone. The primary outcome measure was to compare the improvement of bronchiolitis severity score (BSS) and length of hospitalization. The secondary outcome was to measure the need for noninvasive ventilation, need for admission to intensive care unit (ICU) in the initial visit, to evaluate the safety of magnesium sulphate and need for clinic revisit, hospital readmission and ICU readmission within 2 wk after discharge in both the groups. Results The mean age of children allocated in the control group was 7.4 ± 5.1 mo and 7.7 ± 4.5 mo in the intervention group. There was no significant difference with respect to improvement of BSS or reduced length of hospitalization in both the groups (p > 0.05). BSS monitored sequentially after enrollment at 1, 2, 4, 8, 12, 16, and 24 h did not show statistically significant differences between the groups. Mean length of hospital stay was 2.89 ± 2.25 d in treatment group and 2.96 ± 1.86 d in control group (p = 0.902). No adverse events were observed in both the groups. Conclusion Nebulized magnesium sulphate is not superior to standard therapy in children with moderate to severe bronchiolitis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Amongst the studies on nebulized MgSO 4 , noteworthy is the research by Modaresi et al [ 9 , 13 ]. They conducted two studies with 60 and 120 children in 2012 and 2015, respectively.…”

Section: Discussionmentioning

confidence: 99%